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Introduction 
Terazosin hydrochloride (TER) showed in Figure 1 is a 
α1-adrenoceptor blocker with a long lasting action. α1-
adrenoceptor  antagonists  are  clinically  useful  for  the 
improvement  of  urinary  obstruction  due  to  benign 
prostatic  hyperplasia  (BPH),  and  their  pharmacologic 
effect is mediated through the blockade of prostatic α1-
adrenoceptor.
1-3  It  is  used  in  the  management  of 
hypertension  and  in  benign  prostate  hyperplasia  to 
relieve  symptoms  of  urinary  obstruction.  TER  is 
rapidly  and  almost  completely  absorbed  from  the 
gastrointestinal  tract  after  oral  administration  and  is 
extensively metabolized in the liver to yield piprazine 
and three other inactive metabolites. Absorption is not 
affected by the presence of food. The major route of 
elimination  is  via  the  biliary  tract  and  the  drug  is 
excreted  in  faeces  (60%)  and  urine  (40%).  10%  is 
excreted  as  the  parent  drug  and  the  remainder  as  its 
metabolites.  Renal  impairment  shows  no  significant 
effect on pharmacokinetics.
4 
TER could be determined by using several analytical 
techniques,  potentiometry,
5  voltammetry,
6,7 
spectrophotometry,
8,9 fluorimetry,
10,11 and HPLC.
12-14 
Thermal analysis including TGA, DTG, DTA and DSC 
are  useful  techniques  that  have  been  successfully 
applied  in  the  pharmaceutical  industry  to  reveal 
important  information  regarding  the  physicochemical 
properties  of  drug  and  excipients  such  as 
polymorphism,  stability  and  purity.
15-21  DSC  can  be 
used as an analytical tool of great importance for the 
identification  and  purity  testing  of  active  drugs, 
yielding results rapidly and efficiently. DSC has been 
applied for the quality control of raw materials used in 
pharmaceutical products.
22 
 
 
Figure 1. The molecular structure of TER 
 
The present work represents the study of the thermal 
behavior  of  TER,  in  comparison  with  the  methods 
employed  for  purity  testing  in  the  pharmaceutical 
industry  in  relation  to  the  application  of  thermal 
techniques in the quality control of medications. 
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Purpose:  Thermal  analysis  (TGA,  DTG  and  DTA)  and  differential  scanning 
calorimetry  (DSC)  have  been  used  to  study  the  thermal  behavior  of  terazosin 
hydrochloride (TER). Methods: Thermogravimetric analysis (TGA/DTG), differential 
thermal  analysis  (DTA)  and  differential  scanning  calorimetry  (DSC)  were  used  to 
determine  the  thermal  behavior  and  purity  of  the  used  drug.  Thermodynamic 
parameters such as activation energy (E*), enthalpy (H*), entropy (S*) and Gibbs 
free energy change of the decomposition (G*) were calculated using different kinetic 
models. Results: The purity of the used drug was determined by differential scanning 
calorimetry  (99.97%)  and  specialized  official  method  (99.85%)  indicating  to 
satisfactory  values  of  the  degree  of  purity.  Thermal  analysis  technique  gave 
satisfactory results to obtain quality control parameters such as melting point (273 ºC), 
water content (7.49%) and ash content (zero) in comparison to what were obtained 
using official method: (272
 ºC), (8.0%) and (0.02%) for melting point, water content 
and ash content, respectively. Conclusion: Thermal analysis justifies its application in 
quality control of pharmaceutical compounds due to its simplicity, sensitivity and low 
operational  costs.  DSC  data  indicated  that  the  degree  of  purity  of  terazosin 
hydrochloride is similar to that found by official method. 
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Materials and Methods 
Materials 
Terazosin  hydrochloride  was  provided  from  the 
reference  standard  department  of  NODCAR,  which 
manufactured by Pharaonia Amriya for Pharmaceutical 
Company, Alexandria, Egypt. The purity of terazosin 
hydrochloride  was  found  to  be  99.85%  and  the 
impurities  content  was  found  to  be  0.15%  according 
to the  potentiometric  and  liquid  chromatographic 
methods which reported in the British pharmacopoeia, 
BP 2011.  
Methods 
The  thermal  analysis  of  TER  was  performed  using 
Shimadzu  thermogravimetric  analyzer  TGA-60H  in  a 
dynamic nitrogen atmosphere. Highly sintered α-Al2O3 
was used as a reference. The mass losses of samples 
and  heat  response  of  the  change  of  the  sample  were 
measured  from  room  temperature  up  to  750  ºC.  The 
heating rate was 10 ºC/min. 
Thermodynamic parameters such as activation energy 
(E*),  enthalpy  (ΔH*),  entropy  (ΔS*)  and  Gibbs  free 
energy  change  of  the  decomposition  (ΔG*)  were 
obtained  by  using  the  Horowitz-Metzger  and  Coats-
Redfern  relations  which  applied  for  the  first  order 
kinetic process.
23,24 
Horowitz and Metzger Method
 23 
The Horowitz-Metzger equation can be represented as 
follows:  
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Where Wf was the mass loss at the completion of the 
decomposition  reaction,  W  was  the  mass  loss  up  to 
temperature T, R was the gas constant, Ts was the DTG 
peak temperature and  = T-Ts. A plot of log [log Wf / 
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could be calculated from the slope.  
 
Coats-Redfern Method 
24 
The Coats-Redfern method equation can be represented 
as follows:  
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Where  was the heating rate. Since 1- 2RT / E
*1, the 
plot of the left-hand side of equation against 1/T would 
give  a  straight  line.  E
*  was  then  calculated  from  the 
slope  and  the  Arrhenius  constant  (A)  was  obtained 
from the intercept. 
The entropy S
*, enthalpy H
*, and free energy G
* of 
activation  were  calculated  using  the  following 
equations: 
S
* = 2.303 [log (Ah / kT)] R  
H
* = E
* - RT  
G
* = H
*- Ts S
*  
Where  k  and  h  were  the  Boltzman  and  Planck 
constants, respectively. So the calculated values of E
*, 
S
*, H
*, and G
* could be obtained.
 
DSC curves were measured on Shimadzu DSC-50 cell. 
Approximately  2  mg  of  samples  was  weighed  and 
placed in a sealed aluminum pan. An empty aluminum 
pan was used as a reference. The purity determination 
was performed using a heating rate of 10 ºC/min in the 
temperature  range  from  25  to  320  ºC  in  nitrogen 
atmosphere  with  flow  rate  of  30  ml/min.  DSC 
equipment was calibrated with indium. 
 
Results and Discussion 
Thermal Analysis of TER 
Thermal  analysis  data  containing  thermogravimetric 
analysis (TGA), Derivative thermal analysis (DTG) and 
Differential thermal analysis (DTA) curves of the drug 
are shown in Figure 2. Thermal degradation pattern of 
TER  was  shown  in  Figure  3.  The  weights  losses, 
physical  and  chemical  changes  during  thermal 
degradation of the drug are presented in Table 1.  
 
 
Figure 2. TGA, DTG and DTA curves of TER. 
 
The  TGA  curve  shows  that  TER  is  thermally 
decomposed in four steps. The first step occurs at 25-
150  ºC  as  a  result  of  7.59%  estimated  weight  loss 
which  may  be  due  to  the  loss  of  two  crystal  water 
molecules. The second step occurs at 150-280 ºC with 
about 7.71% weight loss which may be due to the loss 
of HCl molecule. The third step occurs in two stages at 
280-320 ºC with an estimated weight loss of 14.98% 
which may be attributed to the loss of C4H7O molecule 
and  at  320-341  ºC  with  an  estimated  weight  loss  of 
6.18%  which  may  be  attributed  to  the  loss  of  CO 
molecule. The fourth step occurs in two stages at 341-
490 ºC with an estimated weight loss of 18.56% which 
may be attributed to the loss of C4H8N2 molecule and at 
490-700 ºC with an estimated weight loss of 45.31% 
which  may  be  attributed  to  the  loss  of  C10H10N3O2 
molecule.  The  weight  losses  appeared  in  DTA  as 
endothermic  and  exothermic  peaks  which  refer  to 
several chemical processes occur as a result of thermal 
degradation of the used drug at the temperature ranges 
were  given  in  Table  1.  These  results  indicate  the 
compatibility between mass fragmentation and thermal 
degradation of the used drug.
4   
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Figure 3. Thermal degradation pattern of TER. 
Table 1. Thermogravimetric data (TGA, DTG and DTA) of TER. 
Temperature range (ºC)  DTGmax (ºC)  Mass loss (%)  Assignment  DTA
# (ºC) 
25-150  117  7.59  Loss of water molecules  119 (+) 
150-280  275  7.71  Loss of HCl molecule and melting  199 (-), 273 (+) 
280-320  296  14.98  Loss of C4H7O molecule  -------- 
320-341  332  6.18  Loss of CO molecule  -------- 
341-490  433  18.56  Loss of C4H8N2 molecule  367 (-) 
490-700  595  45.31  Loss of C10H10N3O2 molecule  578 (-) 
# (+) = endothermic, (-) = exothermic 
 
Both Horowitz-Metzger (HM) and Coats-Redfern (CR) 
methods  were  applied  for  calculating  the  different 
thermodynamic  parameters  of  the  thermal 
decomposition steps of TER. The results were listed in 
Table 2. 
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Table 2. Thermodynamic parameters of the thermal decomposition of TER 
 
Determination of Purity of TER 
DSC can be successfully used as a complementary or 
an alternative technique to verify purity of a compound 
provided that the material is at least 98% pure. Main 
advantages  of  purity  analysis  by  DSC  are  minimal 
sample  requirement  and  shorter  analysis  time  as 
compared  to  chromatographic  analysis.
25  Van
’t  Hoff 
equation [Tf = T0 – [(R T0
2 X/∆𝐻f). 1/F]] was used to 
determine  the  purity  value,  where  Tf  is  the  melting 
temperature of the sample, T0 is the melting point of 
pure substance in Kelvin (K), R is the gas constant, ∆Hf 
is the heat of fusion, F is the fraction melted and X is 
the mole fraction of impurities. The determination of 
purity is based on the assumption that impurities lower 
the  melting  point  of  a  pure  substance.  The  melting 
transition of a pure, 100% crystalline substance should 
be  infinitely  sharp,  but  impurities  or  defects  in  the 
crystal  structure  will  broaden  the  melting  range  and 
lower the melting point.
26 
DSC  thermogram  of  TER  is  shown  in  Figure  4.  An 
endothermic reaction  with  a broad  peak  at  141
 ºC,  a 
weak exothermic peak at 199
 ºC and an endothermic 
sharp peak at 274
 ºC correspond to the loss of water 
molecules,  the  loss  of  HCl  molecule  and  the  drug 
melting,  respectively.  These  results  are  in  close 
agreement  with  that  obtained  from  the  DTA  profile. 
Applying  DSC  method  and  Van
’t  Hoff  equation 
indicated that the sample is very pure (99.97%). This 
value was in close agreement with the results obtained 
by using the official method (99.85%) confirming low 
impurity content (Table 3).
27 
 
Figure 4. The DSC curve of TER.
 
Table 3. Melting point and degree of purity of TER. 
Melting point (ºC)  Degree of purity (%) 
DTA method  Melting point apparatus  DSC Method  Literature
 4  DSC Method  Official Method
 27 
273  272  274  271-274  99.97%  99.85% 
 
Thermal Analysis Application of TER 
Different quality parameters such as water content and 
ash content were determined by using thermal analysis 
method.  No  significant  difference  was  observed 
between  the  obtained  results  when  compared  with 
reported official method as shown in Table 4.
 27 
Table 4. Quality control parameters obtained from the thermal analysis of TER compared with reported method 
Water content (% )  Ash content (% ) 
Thermal analysis method  Reported method 
27  Thermal analysis method  Reported method
 27 
7.49  8.0   (7.0-8.6)  zero  0.02     (Max. 0.1%) 
   
 
Temperature range (ºC) 
 
E* 
(kJ/mol) 
HM (CR) 
A 
(S
-1) 
HM (CR) 
S* 
(kJ/mol. K) 
HM (CR) 
H* 
(kJ/mol) 
HM (CR) 
G* 
(kJ/mol) 
HM (CR) 
25-150 
152.10 
(131.47) 
2.84×10
17 
(9.50×10
16) 
144.44 
(77.88) 
148.87 
(128.23) 
92.53 
(97.85) 
150-280 
51.81 
(53.42) 
6.47×10
-2 
(2.41×10
-3) 
-272.78 
(-300.15) 
625.39 
(782.71) 
150.11 
(165.26) 
280-320 
112.95 
(104.70) 
9.82×10
9 
(8.55×10
8) 
-59.01 
(-79.31) 
108.21 
(99.96) 
141.80 
(145.09) 
320-341 
132.31 
(121.38) 
1.16×10
11 
(1.30×10
10) 
-39.02 
(-57.20) 
127.29 
(116.34) 
150.89 
(150.95) 
341-490 
32.35 
(18.80) 
1.93×10 
(1.14) 
-227.49 
(-251.05) 
26.48 
(12.93) 
187.10 
(190.17) 
490-700 
121.18 
(99.67) 
3.79×10
6 
(7.61×10
4) 
-127.87 
(-160.37) 
113.96 
(92.45) 
224.95 
(231.65)  
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Conclusion 
The  comparison  between  mass  fragmentation  and 
thermal degradation of TER could show the agreement 
or the disagreement between the two techniques used in 
studying  the  drug  fragmentation  pathways.  The 
obtained  results  indicate  the  compatibility  between 
mass fragmentation  and thermal  degradation of  TER. 
Therefore fragmentation pathway of TER was correctly 
determined. Thermal analysis methods are widely used 
in  all  fields  of  pharmaceutical  sciences.  These 
techniques  are  unique  for  the  characterization  of 
compounds  and  mixtures.  Differential  scanning 
calorimetry  provides  a  satisfactory  result  for  purity 
determination  of  the  drug  when  compared  with  the 
official methods. Thermal analysis method might be a 
very  useful  tool  to  determine  some  quality  control 
parameters  such  as  water  content  and  ash  content 
comparing with  results obtained  by using  the  official 
methods. 
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